Cetera Investment Advisers
BMRN icon

Cetera Investment Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cetera Investment Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$931K Sell
16,275
-13,705
-46% -$751K ﹤0.01% 3119
2026
Q1 		$1.69M Sell
29,980
-6,943
-19% -$405K ﹤0.01% 2440
2025
Q4 		$2.19M Sell
36,923
-3,156
-8% -$172K ﹤0.01% 2129
2025
Q3 		$2.17M Buy
40,079
+15,783
+65% +$903K ﹤0.01% 2101
2025
Q2 		$1.34M Sell
24,296
-4,959
-17% -$292K ﹤0.01% 2139
2025
Q1 		$2.07M Buy
29,255
+17,931
+158% +$1.21M ﹤0.01% 1726
2024
Q4 		$744K Buy
11,324
+3,870
+52% +$259K ﹤0.01% 2374
2024
Q3 		$524K Sell
7,454
-4,238
-36% -$354K ﹤0.01% 2611
2024
Q2 		$963K Sell
11,692
-4,357
-27% -$363K ﹤0.01% 2103
2024
Q1 		$1.4M Buy
16,049
+11,030
+220% +$987K ﹤0.01% 1806
2023
Q4 		$484K Buy
5,019
+194
+4% +$17.2K ﹤0.01% 1509
2023
Q3 		$427K Buy
4,825
+238
+5% +$21.2K ﹤0.01% 1508
2023
Q2 		$398K Buy
4,587
+1,057
+30% +$99.5K ﹤0.01% 1578
2023
Q1 		$343K Buy
3,530
+59
+2% +$6.12K ﹤0.01% 1628
2022
Q4 		$359K Buy
3,471
+371
+12% +$34.8K ﹤0.01% 1549
2022
Q3 		$263K Sell
3,100
-189
-6% -$16.8K 0.01% 1358
2022
Q2 		$273K Sell
3,289
-2,670
-45% -$213K ﹤0.01% 1482
2022
Q1 		$459K Sell
5,959
-511
-8% -$42.8K 0.01% 1217
2021
Q4 		$572K Buy
6,470
+370
+6% +$30.5K 0.01% 1105
2021
Q3 		$471K Buy
6,100
+483
+9% +$38.1K 0.01% 1178
2021
Q2 		$469K Buy
+5,617
New +$445K 0.01% 1154
2021
Q1 		– Sell
-2,695
Closed -$236K – 1609
2020
Q4 		$236K Buy
+2,695
New +$214K ﹤0.01% 1376

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Cetera Investment Advisers's BMRN Position: Q2 2026 in Review

Cetera Investment Advisers reduced its BioMarin Pharmaceuticals (BMRN) stake by 46% in Q2 2026, selling an estimated $751K and leaving 16,275 shares worth $931K. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

Cetera Investment Advisers first reported a position in BMRN in Q4 2020 and has held it in 22 quarters since. The position peaked at $2.19M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Cetera Investment Advisers held 16,275 shares of BioMarin Pharmaceuticals worth $931K as of Q2 2026.
  • Cetera Investment Advisers sold 13,705 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $751K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #3119 holding.
  • Cetera Investment Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Cetera Investment Advisers's BioMarin Pharmaceuticals position peaked at $2.19M in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.